The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10872 malaria professionals are enjoying the free benefits of MalariaWorld today

pyronaridine tetraphosphate

Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease

October 7, 2020 - 14:45 -- Open Access
Author(s): 
Lane TR, Dyall J, Mercer L, Goodin C, Foil DH, Zhou H, Postnikova E, Liang JY, Holbrook MR, Madrid PB, Ekins S
Reference: 
Antiviral Res. 2020 Oct;182:104908

We have recently identified three molecules (tilorone, quinacrine and pyronaridine tetraphosphate) which all demonstrated efficacy in the mouse model of infection with mouse-adapted Ebola virus (EBOV) model of disease and had similar in vitro inhibition of an Ebola pseudovirus (VSV-EBOV-GP), suggesting they interfere with viral entry.

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection

November 30, 2019 - 20:12 -- Open Access
Author(s): 
Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S
Reference: 
PLoS Negl Trop Dis. 2019 Nov 21;13(11):e0007890.

Recent outbreaks of the Ebola virus (EBOV) have focused attention on the dire need for antivirals to treat these patients. We identified pyronaridine tetraphosphate as a potential candidate as it is an approved drug in the European Union which is currently used in combination with artesunate as a treatment for malaria (EC50 between 420 nM-1.14 μM against EBOV in HeLa cells).

Subscribe to RSS - pyronaridine tetraphosphate